Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammi’s lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.
View Top Employees from Nammi Therapeutics, Inc.Website | http://www.nammirx.com |
Revenue | $200000 |
Employees | 7 (6 on RocketReach) |
Address | 10940 WILSHIRE BLVD STE 600, Los Angeles, California 90024, US |
Technologies |
JavaScript,
HTML,
Twitter
+7 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Business Services |
Competitors | CUBIO Innovation Center, Intensity Therapeutics, Inc., Tactiva Therapeutics, Targepeutics, Veana Therapeutics Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies |
Looking for a particular Nammi Therapeutics, Inc. employee's phone or email?
The Nammi Therapeutics, Inc. annual revenue was $200000 in 2024.
Joseph Rice is the Executive Vice President of Operations of Nammi Therapeutics, Inc..
6 people are employed at Nammi Therapeutics, Inc..
Nammi Therapeutics, Inc. is based in Los Angeles, California.
The NAICS codes for Nammi Therapeutics, Inc. are [5417, 54171, 54, 541, 541714].
The SIC codes for Nammi Therapeutics, Inc. are [87, 873].